Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Nonacog alfa
BIOLOGICAL
3 trials
Sponsors
Medexus Pharma, Inc.
, Pfizer
Conditions
Hemophilia B
Phase 2
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
Completed
NCT00768287
Medexus Pharma, Inc.
Hemophilia B
Start: 2009-01-31
End: 2016-12-31
Updated: 2021-04-06
Phase 3
Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
Completed
NCT01335061
Pfizer
Hemophilia B
Start: 2011-09-30
End: 2014-04-30
Updated: 2015-06-08
Phase 4
Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B
Completed
NCT04286412
Pfizer
Hemophilia B
Start: 2020-02-10
End: 2020-09-24
Updated: 2022-07-01
Related Papers
Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B
Clinical Pharmacokinetics
2025-08-01
4 citations
Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset
Blood Coagulation & Fibrinolysis
2021-01-20
2 citations
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
2012-07-05
21 citations